FibroGen, Inc. (BMV:FGEN)

Mexico flag Mexico · Delayed Price · Currency is MXN
6.69
-0.01 (-0.15%)
At close: May 6, 2025, 2:00 PM CST
-69.27%
Market Cap 645.70M
Revenue (ttm) 617.22M
Net Income (ttm) -991.42M
Shares Out n/a
EPS (ttm) -9.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 33
Average Volume 1,111
Open 6.73
Previous Close 6.70
Day's Range 6.69 - 6.73
52-Week Range 5.00 - 22.45
Beta 0.88
RSI 51.00
Earnings Date May 5, 2025

About FibroGen

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 225
Stock Exchange Mexican Stock Exchange
Ticker Symbol FGEN
Full Company Profile

Financial Performance

In 2024, FibroGen's revenue was $29.62 million, a decrease of -36.71% compared to the previous year's $46.80 million. Losses were -$47.58 million, -83.26% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.